It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hepatitis B virus (HBV) only infects humans and chimpanzees, posing major challenges for modeling HBV infection and chronic viral hepatitis. The major barrier in establishing HBV infection in non-human primates lies at incompatibilities between HBV and simian orthologues of the HBV receptor, sodium taurocholate co-transporting polypeptide (NTCP). Through mutagenesis analysis and screening among NTCP orthologues from Old World monkeys, New World monkeys and prosimians, we determined key residues responsible for viral binding and internalization, respectively and identified marmosets as a suitable candidate for HBV infection. Primary marmoset hepatocytes and induced pluripotent stem cell-derived hepatocyte-like cells support HBV and more efficient woolly monkey HBV (WMHBV) infection. Adapted chimeric HBV genome harboring residues 1–48 of WMHBV preS1 generated here led to a more efficient infection than wild-type HBV in primary and stem cell derived marmoset hepatocytes. Collectively, our data demonstrate that minimal targeted simianization of HBV can break the species barrier in small NHPs, paving the path for an HBV primate model.
Hepatitis B virus is an almost uniquely human-tropic pathogen for which model systems are scarce. Here, the authors determine key residues within the HBV receptor that form a barrier in the HBV life cycle in primates and identify marmosets as a model candidate for infection with simian-tropic HBV.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Princeton University, Department of Molecular Biology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006)
2 Princeton University, Department of Molecular Biology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006); Princeton University, Research Computing, Office of Information Technology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006)
3 Princeton University, Department of Molecular Biology, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006); Memorial Sloan-Kettering Cancer Center, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)
4 Visikol, Inc., Hampton, USA (GRID:grid.51462.34)
5 Weill Cornell Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
6 Boston University, National Emerging Infectious Diseases Laboratories, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
7 Boston University, National Emerging Infectious Diseases Laboratories, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University Chobanian & Avedisian School of Medicine, Department of Pathology and Laboratory Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)